Taiwan Advance Bio-Pharmaceutical EBIT

Taiwan Advance Bio-Pharmaceutical (4186.TWO) currently reports a EBIT of $48M as of June 2026. That compares with $-39M in the prior-year period — up 220.8% year over year. That is below the Healthcare sector average of $130B. Use the charts on this page to explore Taiwan Advance Bio-Pharmaceutical's EBIT history and peer comparisons.

Taiwan Advance Bio-Pharmaceutical's EBIT increased from $-39M to $48M — a 220.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Taiwan Advance Bio-Pharmaceutical's EBIT of $48M is lower than the Healthcare sector average of $130B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Taiwan Advance Bio-Pharmaceutical reported $48M in EBIT as of June 2026. That compares with $-39M in the prior-year period — up 220.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $48M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $130B. From there, open related valuation or income-statement pages for Taiwan Advance Bio-Pharmaceutical, and consider following 4186.TWO for alerts when major investors trade the stock.